Brain and Central Nervous System Tumors Clinical Trial
Official title:
A Randomized, Controlled Comparative Trial to Determine if Testosterone Gel Prevents Steroid Related Weakness in Brain Cancer Patients
RATIONALE: Testosterone gel may be effective in preventing or lessening muscle weakness
caused by steroid therapy in men receiving glucocorticoids for newly diagnosed high-grade
glioma.
PURPOSE: This randomized clinical trial is studying how well testosterone gel works in
preventing weakness caused by steroid therapy in men receiving glucocorticoids for newly
diagnosed high-grade glioma.
OBJECTIVES:
Primary
- To determine if daily administration of testosterone gel can prevent the development or
reduce the severity of muscle weakness in men receiving glucocorticoids for newly
diagnosed high-grade glioma.
Secondary
- To compare the difference in percent change from baseline timed functional tests (TFT)
between patients who are treated with testosterone gel and those who are not.
- To compare the difference in percent change from baseline activities of daily living as
assessed by the Health Assessment Questionnaire-Disability Index (HAQ-DI) between
patients who are treated with testosterone gel and those who are not.
- To compare the difference in percent change from baseline leg muscle mass as assessed by
CT scan imaging between patients who are treated with testosterone gel and those who are
not.
- To estimate the side effects of testosterone gel in these patients.
OUTLINE: Patients are stratified according to daily glucocorticoid dose (< 16 mg/day vs ≥ 16
mg/day), Karnofsky performance status (≤ 80% vs > 80%), and age (≤ 50 years of age vs > 50
years of age). Patients are randomized to 1 of 2 treatment arms.
- Arm I (control): Patients receive oral whey protein powder once daily for 7 months.
- Arm II (treatment): Patients apply topical testosterone gel to the shoulder, upper
chest, or forearm once daily for 7 months.
Patients undergo strength testing and functional testing (TFT) and complete an activities of
daily living questionnaire at baseline and at 1, 3, 5, and 7 months. Patients also undergo CT
scan of the leg and laboratory testing at baseline and at 3 and 7 months. Testosterone levels
are obtained at baseline and at 1, 3, and 7 months.
Patients complete a daily log of their glucocorticoid dose and to affirm compliance with
therapy. Major clinical events related to underlying tumor (i.e., surgery, radiotherapy,
initiating chemotherapy, concurrent antiepileptic therapy, deep vein thrombosis, pulmonary
embolism, transfusions, seizures, pneumonia, and other forms of infection) are also recorded.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT00006080 -
Fenretinide in Treating Patients With Recurrent Malignant Glioma
|
Phase 2 | |
Recruiting |
NCT00887146 -
Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma
|
Phase 3 | |
Suspended |
NCT00935090 -
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
|
N/A | |
Completed |
NCT00621686 -
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
|
Phase 2 | |
Completed |
NCT00112502 -
Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme
|
Phase 2 | |
Terminated |
NCT00227032 -
Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme
|
Phase 1 | |
Terminated |
NCT00243022 -
Dietary, Herbal and Alternative Medicine in Glioblastoma Multiforme
|
Phase 2 | |
Active, not recruiting |
NCT00087815 -
Hyperbaric Oxygen Therapy in Treating Patients With Radiation Necrosis of the Brain
|
N/A | |
Active, not recruiting |
NCT00278278 -
Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas
|
Phase 3 | |
Completed |
NCT00416819 -
Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Primary CNS Lymphoma
|
N/A | |
Completed |
NCT00052286 -
Modafinil in Treating Fatigue and Behavioral Change in Patients With Primary Brain Cancer
|
N/A | |
Completed |
NCT00006093 -
EMD 121974 in Treating Patients With Progressive or Recurrent Glioma
|
Phase 1/Phase 2 | |
Recruiting |
NCT00004129 -
Phosphorus 32 in Treating Patients With Glioblastoma Multiforme
|
Phase 1 | |
Completed |
NCT00004212 -
DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
Completed |
NCT00003417 -
Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme
|
Phase 1/Phase 2 | |
Completed |
NCT00008008 -
Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma
|
Phase 2 | |
Completed |
NCT00003484 -
Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors
|
Phase 1 | |
Completed |
NCT00003173 -
High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors
|
Phase 2 | |
Completed |
NCT00003020 -
LMB-7 Immunotoxin in Treating Patients With Leptomeningeal Metastases
|
Phase 1 |